AtriCure, Inc. (ATRC) Earnings Call Analysis

NASDAQ · Healthcare · Medical Instruments & Supplies

Earnings Reports

• AtriCure (ATRC) Q2 2026: Pain Management Franchise Delivers 28% U.S. Growth, Extending Platform Lead
  July 24, 2026
• AtriCure (ATRC) Q1 2026: Gross Margin Expands 246 bps on U.S. Product Mix Surge
  May 06, 2026
• AtriCure (ATRC) Q4 2025: Open Appendage Management Jumps 24%, Offsetting Hybrid Decline
  February 24, 2026
• AtriCure (ATRC) Q2 2025: Pain Management Franchise Surges 43%, Accelerating Non-Opioid Adoption
  July 29, 2025
• AtriCure (ATRC) Q1 2025: Flex Mini Drives 23% U.S. Open Growth, Extending Franchise Tailwinds
  July 06, 2025
• AtriCure (ATRC) Q3 2024: Pain Management Franchise Grows 36%, Fueling Cash Generation and Portfolio Expansion
  October 29, 2024
• Atricure (ATRC) Q2 2024: International Revenue Jumps 29%, Offsetting U.S. Hybrid Headwinds
  July 30, 2024
• AtriCure (ATRC) Q1 2024: Open Ablation Sales Up 16.5% as Innovation Offsets Competitive Pressure
  May 01, 2024

Browse all companies